Clinical effectiveness and safety of low cost versus innovator brand amlodipine in hypertension: A single-blinded, randomized, crossover, noninferiority trial | Zendy

AlakKumar Das | Zendy; Suparna Chatterjee | Zendy; Jyotirmoy Pal | Zendy

Open Access

Clinical effectiveness and safety of low cost versus innovator brand amlodipine in hypertension: A single-blinded, randomized, crossover, noninferiority trial

Author(s) -

AlakKumar Das,

Suparna Chatterjee,

Jyotirmoy Pal

Publication year - 2016

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.194844

Subject(s) - amlodipine , medicine , crossover study , blood pressure , confidence interval , randomized controlled trial , diastole , innovator , essential hypertension , placebo , alternative medicine , pathology , intellectual property , computer science , operating system

A single-blinded, randomized, crossover, noninferiority trial was conducted to evaluate clinical effectiveness and safety of low-cost brand (LCB) versus innovator brand (IB) amlodipine in essential hypertension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research